Amgen Asserts No Error In Requiring Approval Before 180-Day Notice
WASHINGTON, D.C. — Amgen Inc. filed its opening and response brief on March 10 in its high-stakes suit with Sandoz Inc., arguing that the Federal Circuit U.S. Court of Appeals did...To view the full article, register now.
Already a subscriber? Click here to view full article